Update on infectious disease prevention: human papillomavirus, hepatitis A.
Key studies on the prevention of human papillomavirus and hepatitis A published during the past year found that: A quadrivalent vaccine against human papillomavirus prevents cervical intraepithelial neoplasia, vulvar and vaginal intraepithelial neoplasia, and anogenital disease in young women. The vaccine is likely cost-effective when given to girls, but perhaps not when given to boys. Although hepatitis A immune globulin is modestly better than hepatitis A vaccine for postexposure prophylaxis against hepatitis A, both are highly effective. Hepatitis A vaccine is now recommended by the Advisory Committee on Immunization Practices as the preferred agent in healthy individuals between the ages of 2 and 40.
Longworth
David L
DL
Department of Medicine, Tufts University School of Medicine, USA. david.longworth@bhs.org
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006506:Hepatitis A / Q000517:prevention & control*; D022362:Hepatitis A Vaccines; D030041:Hepatitis A virus / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology; D014625:Vaginal Neoplasms / Q000517:prevention & control / Q000821:virology
D022362:Hepatitis A Vaccines; D016756:Immunoglobulins, Intravenous; D053918:Papillomavirus Vaccines